EWTX - NASDAQ
Edgewise Therapeutics, Inc.
$36.21
-1.7%Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has completed Phase 1 clinical trial. It develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.
At a Glance
Live SnapshotNo Revenue Data
EWTX has not reported any revenue values in the available annual periods.
Edgewise Therapeutics, Inc. Profit Bridge
Profitability Analysis
Edgewise Therapeutics, Inc. Income Statement
EWTX • NASDAQ
| Edgewise Therapeutics, Inc. Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|---|
REVENUE | |||||||
GROSS PROFIT | |||||||
(2.3M) | (0.0) | (0.0) | (0.0) | (0.0) | (185K) | (123K) | |
-2.3M | 0.0 | 0.0 | 0.0 | 0.0 | -185K | -123K | |
OPERATING INCOME | |||||||
(189.1M) | (158.8M) | (114.4M) | (71.7M) | (43.2M) | (17M) | (9.9M) | |
(40M) | (31.9M) | (23.5M) | (17.6M) | (11M) | (2.2M) | (1.3M) | |
(151.4M) | (127M) | (90.9M) | (54M) | (32.2M) | (14.8M) | (8.6M) | |
-191.4M | -158.8M | -114.4M | -71.7M | -43.2M | -17.2M | -9.9M | |
PRE-TAX INCOME | |||||||
(0.0) | (0.0) | (0.0) | (4M) | (0.0) | (0.0) | (0.0) | |
23.6M | 25M | 14.2M | -1.4M | 402K | 69K | 219K | |
-2.3M | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
23.6M | 25M | 14.2M | 4M | 402K | 69K | 219K | |
-167.8M | -133.8M | -100.2M | -67.6M | -42.8M | -17.1M | -9.7M | |
NET INCOME | |||||||
-167.8M | -133.8M | -100.2M | -67.6M | -42.8M | -17.1M | -9.5M |
SEC Filings
EWTX - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | June 01, 2026 | May 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 07, 2026 | May 07, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 07, 2026 | March 31, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 23, 2026 | June 04, 2026 | 2026 | |
10-K 10-K 2025 FY FY | February 26, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | February 26, 2026 | February 26, 2026 | 2026 | |
8-K 8-K 2025 N/A | November 20, 2025 | November 19, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 10, 2025 | November 10, 2025 | 2025 | |
10-Q 10-Q 2025 Q3 Q3 | November 06, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 06, 2025 | November 06, 2025 | 2025 |
Related Guides
Continue your EWTX research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.